Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
GRDX Catalyst Timeline
Dated clinical, regulatory and corporate events for GridAI Technologies Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for GridAI Technologies Corp.
Event history 50
Past FDA Catalysts and PDUFA Decisions
How GRDX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every GRDX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| adrulipase | exocrine pancreatic insufficiency (EPI) in cystic fibrosis patients | Phase 2 | 2023-07-13 | the enhanced adrulipase formulation was safe and well tolerated and demonstrated an improvement over prior formulations of adrulipaseRead More | First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase FormulationRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sawyer Jason DavidDirector, Officer (Chief Executive Officer) | Grant/Award | 250,000 540,000 held | $0.00 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GRDX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in GRDX for Q3 2026. | ||||
Ownership Trends
GRDX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How GRDX ranks across every disease it competes in
GRDX News
GridAI Technologies Signs Definitive Agreement to Acquire Pronghorn Resources, Establishing Major Wyoming Owned-Natural Gas and Multi-Gigawatt AI Power Infrastructure Platform Targeting Initial Power Delivery in 2027
GridAI Technologies has signed a Definitive Share Exchange Agreement to acquire Pronghorn Resources, establishing a significant energy infrastructure platform in Wyoming. The acquisition aims to support the growing demand for AI data centers, targeting 300 MW of initial power delivery by 2027. GridAI plans to leverage Pronghorn's existing assets to enhance its operational capabilities.
Read more →GridAI Technologies Corp. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
GridAI Technologies Corp. announced that it received a notice from Nasdaq regarding its late Form 10-K filing, indicating non-compliance with requirements for continued listing. The company must submit a plan to regain compliance by June 22, 2026. If accepted, Nasdaq may grant an extension of up to 180 days. However, there are no guarantees that the plan will be accepted, raising concerns about future compliance.
Read more →Eric Corbett 100 Long Branch Avenue Unit 21 Etobicoke, Ontario, M8W 0C1 CANADA Via Email (jason@accessalternative.com; edborkowski@gmail.com)
Eric Corbett has announced his resignation from the Board of Directors of Entero Therapeutics Inc., effective November 28, 2025. The resignation stems from fundamental disagreements with the management and the Board's policies and practices. This internal conflict may raise concerns regarding the company's governance and future strategic decisions.
Read more →ENTERO THERAPEUTICS (NASDAQ: ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data
Entero Therapeutics, Inc. (NASDAQ: ENTO) has acquired GRID AI Corp, a grid-edge AI platform, in a strategic move to enhance its position in the burgeoning AI-driven energy infrastructure market. This acquisition is expected to allow ENTO to effectively address the rising electricity demand from data centers, projected to surge significantly in the coming years. GRID AI's platform aims to facilitate dynamic load management and improve grid reliability by integrating flexible demand from various energy resources. Following regulatory approval, GRID AI will operate as a wholly owned subsidiary of ENTO, enabling expansion into new energy capacities and market opportunities.
Read more →Entero Therapeutics, Inc. Announces Reverse
Entero Therapeutics, Inc. has announced a 1 for 3 reverse stock split to comply with Nasdaq's listing requirements, effective August 18, 2025. This split aims to address the minimum bid price requirement and reduce the outstanding shares from approximately 4.77 million to about 1.59 million. Interim CEO Richard Paolone emphasized the importance of the Nasdaq listing for enhancing shareholder value. No fractional shares will be issued, with affected shareholders receiving cash instead.
Read more →Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules
Entero Therapeutics, Inc. has announced a private placement of approximately $3 million with institutional investors, priced at market under Nasdaq rules. The transaction involves the sale of pre-funded and common warrants, providing significant flexibility for investors. The proceeds are intended for general corporate purposes and working capital. The expected closing date for the transaction is August 11, 2025, pending customary closing conditions. This offering reflects Entero's ongoing efforts to support its development of targeted therapies for gastrointestinal diseases.
Read more →Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC.
Entero Therapeutics announced the signing of a rescission agreement with ImmunogenX to unwind a previously closed business combination. This decision, made after an internal review, is viewed as a strategic move to strengthen Entero's balance sheet and focus on long-term success. Furthermore, the company appointed Anna Skowron as its new Chief Financial Officer, bringing valuable experience in financial reporting and corporate governance. However, the agreement is contingent on obtaining shareholder approval by June 30, 2025.
Read more →Therapeutics Appoints Richard Paolone as CEO
Entero Therapeutics, Inc. has appointed Richard Paolone as interim CEO, bringing a wealth of experience in corporate finance, securities law, and mergers and acquisitions. Paolone is expected to leverage his expertise to guide the company in a competitive market. Entero specializes in developing targeted therapies for gastrointestinal diseases, with drugs in its pipeline aimed at significant unmet medical needs.
Read more →Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company Proposed merger to create N
Entero Therapeutics has announced a proposed reverse merger with Journey Therapeutics, a clinical-stage biopharmaceutical company specializing in nano-immunoconjugates for cancer treatment. Following the merger, shareholders of Journey will control 99% of the combined entity, which will operate under the Journey Therapeutics name. The merger aims to enhance Entero's existing clinical assets while advancing Journey's novel therapies targeting difficult cancers. However, the merger is subject to various conditions, including financing and regulatory approvals.
Read more →Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings Entero Therapeutics to integrate applications in plann
Entero Therapeutics has signed a Letter of Intent with Data Vault Holdings to license and commercialize innovative clinical trial management technologies, including QOLPOM and FotoDigm. This partnership aims to enhance compliance in clinical trials, starting with a Phase 3 trial for latiglutenase in celiac disease. The transaction hinges on securing a strategic investment which would provide significant capital and support for technology development. Should the technologies prove effective in trials, they could lead to broader applications in the pharmaceutical sector.
Read more →Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
Entero Therapeutics, Inc. announced it received a notification from Nasdaq regarding its failure to file the Quarterly Report on Form 10-Q for the fiscal quarter that ended June 30, 2024. The company has until October 21, 2024, to submit a compliance plan to Nasdaq, which may extend the deadline for filing up to February 17, 2025, if approved. Alongside this, Entero Therapeutics is in the process of retaining a new independent registered public accounting firm after its previous firm resigned. However, there remains uncertainty regarding the company's ability to meet Nasdaq's compliance criteria.
Read more →Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
Entero Therapeutics' Chairman and CEO James Sapirstein provided a business update focusing on the development of latiglutenase, a treatment for celiac disease. The company aims to advance latiglutenase into a pivotal Phase 3 trial by 2025 and is adjusting its trial design based on previous discussions with the FDA. Entero has secured $1.9 million in financing and has streamlined its operations to support this process. Their approach reflects a strong commitment to meeting the treatment needs for patients with celiac disease.
Read more →Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds
Entero Therapeutics, Inc. announced the exercise of existing warrants and issuance of new ones in a private placement, resulting in approximately $1.9 million in gross proceeds. The existing warrants, totaling 1,762,674 shares, will be exercised at a reduced price of $1.09 per share. In exchange, the holders will receive new warrants for an additional 3,525,348 shares at the same exercise price, pending stockholder approval. This strategy aims to strengthen Entero's financial capabilities to further develop its innovative therapies for gastrointestinal diseases.
Read more →First Wave BioPharma Changes Name to Entero Therapeutics Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset - latiglutenase for the treatment of celiac disease New Nasdaq new ticker s
First Wave BioPharma has changed its name to Entero Therapeutics as it prepares for a Phase 3 clinical trial of its lead asset, latiglutenase, aimed at treating celiac disease. The rebranding reflects the company's commitment to addressing unmet gastrointestinal health needs. The new ticker symbol ENTO will be effective on May 17, 2024. Additionally, Entero is collaborating with Celiac Journey to promote awareness about celiac disease during Celiac Awareness Month. The success of the Phase 3 trial and the integration of ImmunogenX assets presents both opportunities and challenges for Entero's future.
Read more →First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
First Wave BioPharma, Inc. has announced a definitive securities purchase agreement to raise approximately $1.1 million through the sale of 366,000 shares priced at $2.95 each. Additionally, the agreement includes warrants for purchasing another 732,000 shares at an exercise price of $2.70. The proceeds from this offering will be utilized for general corporate purposes and working capital. Roth Capital Partners is acting as the exclusive placement agent for this transaction, which is expected to close around May 14, 2024.
Read more →First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference Poster presentations to highlight new quantitative and serologic diagn
First Wave BioPharma announced that two research abstracts on celiac disease have been accepted for presentation at the 2024 Digestive Disease Week Conference. These presentations will focus on new diagnostic methods, including the VCIEL scale for measuring mucosal health and the dynamics of serologic changes in patients. The findings are expected to contribute significantly to the understanding and management of celiac disease, highlighting advancements in gastroenterology. The conference will take place from May 18-21, 2024, in Washington, D.C.
Read more →First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline Latiglutenase is a potentially first-in-class oral biot
First Wave BioPharma has successfully completed its acquisition of ImmunogenX, integrating latiglutenase into its pipeline as a Phase 3-ready treatment for celiac disease. The merger aims to enhance First Wave's capabilities in developing targeted therapies for gastrointestinal diseases. Latiglutenase has shown promising results in earlier trials and is expected to enter Phase 3 trials in early 2025, following FDA approval of its clinical development plan. The company plans to license commercial rights for the drug to a global pharmaceutical partner and seeks additional financing to support its development efforts.
Read more →First Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering
First Wave BioPharma, Inc. has announced a registered direct offering, aiming to raise approximately $4.0 million by selling 525,625 shares of common stock at a price of $7.61 per share. Alongside this, the company will issue warrants to purchase up to the same number of shares at an exercise price of $7.48 per share. The gross proceeds from the offering are designated for working capital and general corporate needs. Roth Capital Partners is acting as the exclusive placement agent, with the closing expected around March 6, 2024, pending customary conditions.
Read more →First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024 Multiple clinical and development milestones anticipated in 2024, including initiation of Phase
First Wave BioPharma's Chairman and CEO, James Sapirstein, issued a letter to shareholders outlining recent achievements and the company's 2024 outlook. Key highlights include a potential merger with ImmunogenX, which would provide access to the Phase 3-ready latiglutenase for celiac disease. The company anticipates major clinical and development milestones in 2024, alongside strategic investments for commercial rights. First Wave aims to strengthen its late-stage clinical pipeline focused on gastrointestinal disorders.
Read more →First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 L
First Wave BioPharma has announced its intention to streamline its clinical pipeline by entering a non-binding term sheet for the sale of its Niclosamide program, which targets inflammatory bowel diseases. This strategic decision will allow the company to focus its efforts on advancing three key late-stage clinical programs, including a Phase 3-ready treatment for celiac disease and other GI-focused therapies. The transaction is expected to close in the first half of 2024, pending various regulatory approvals and financing conditions. The sale aims to infuse the company with additional capital to bolster its development resources.
Read more →